These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 17462572)

  • 1. Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening.
    Yang J; Shamji A; Matchacheep S; Schreiber SL
    Chem Biol; 2007 Apr; 14(4):371-7. PubMed ID: 17462572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway.
    Lohar MV; Mundada R; Bhonde M; Padgaonkar A; Deore V; Yewalkar N; Bhatia D; Rathos M; Joshi K; Vishwakarma RA; Kumar S
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3603-6. PubMed ID: 18501601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting atra-induced differentiation.
    Billottet C; Banerjee L; Vanhaesebroeck B; Khwaja A
    Cancer Res; 2009 Feb; 69(3):1027-36. PubMed ID: 19176369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
    Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raptor-rictor axis in TGFbeta-induced protein synthesis.
    Das F; Ghosh-Choudhury N; Mahimainathan L; Venkatesan B; Feliers D; Riley DJ; Kasinath BS; Choudhury GG
    Cell Signal; 2008 Feb; 20(2):409-23. PubMed ID: 18068336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
    Baumann P; Mandl-Weber S; Emmerich B; Straka C; Schmidmaier R
    Exp Cell Res; 2007 Oct; 313(16):3592-603. PubMed ID: 17669398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photodynamic therapy targets the mTOR signaling network in vitro and in vivo.
    Weyergang A; Berg K; Kaalhus O; Peng Q; Selbo PK
    Mol Pharm; 2009; 6(1):255-64. PubMed ID: 19125612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P; Mateo J
    Oncogene; 2009 Jan; 28(3):313-24. PubMed ID: 18978810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors.
    Moreno A; Akcakanat A; Munsell MF; Soni A; Yao JC; Meric-Bernstam F
    Endocr Relat Cancer; 2008 Mar; 15(1):257-66. PubMed ID: 18310292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth.
    Yang X; Yang C; Farberman A; Rideout TC; de Lange CF; France J; Fan MZ
    J Anim Sci; 2008 Apr; 86(14 Suppl):E36-50. PubMed ID: 17998426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using isoform-specific inhibitors to target lipid kinases.
    Simon JA
    Cell; 2006 May; 125(4):647-9. PubMed ID: 16713558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of class III (Vps34) PI3Ks.
    Yan Y; Backer JM
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):239-41. PubMed ID: 17371248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell biology: regulated self-cannibalism.
    Klionsky DJ
    Nature; 2004 Sep; 431(7004):31-2. PubMed ID: 15343317
    [No Abstract]   [Full Text] [Related]  

  • 20. Structure-activity relationship analysis of a novel necroptosis inhibitor, Necrostatin-5.
    Wang K; Li J; Degterev A; Hsu E; Yuan J; Yuan C
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1455-65. PubMed ID: 17270434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.